Arthur S. Leibowitz

Directeur

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 1 buy · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (2 ops.)

€25k

▼ Sales (0 ops.)

—

Latest filing published 11 Mar 2026 for Organogenesis Holdings Inc., €12k. Read the official filing

Filing timeline

BuySale

Arthur S. Leibowitz

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-6.8%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Arthur S. Leibowitz: trading record in brief

Arthur S. Leibowitz, listed as senior executive, appears in our data through filings on Organogenesis Holdings Inc. shares, published by SEC (Form 4). We count 8 filings; the first trade dates from 3 August 2021 and the latest from 9 March 2026.

No open-market sale appears; the market trades are 2 purchases worth €25k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 6 share grants. So far in 2026, the count stands at 1 purchase and no sales.

Most recently, on 11 March 2026, the filings show an open-market purchase worth €12k in Organogenesis Holdings Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.